ID

42539

Descrição

Study ID: 105874 Clinical Study ID: 105874 Study Title: Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00307021 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/NCT00307021. A Phase II randomized, double-blind bridging study of the safety and immunogenicity of GlaxoSmithKline Plasmodium falciparum malaria vaccine RTS,S/AS01E (0.5 mL dose) to RTS,S/AS02D (0.5 mL dose) administered IM according to a 0, 1, 2- month vaccination schedule in children aged 18 months to 4 years living in Gabon. Clinical Visits: This study has a total of 7 visits. Visit 1 = Screening, Visits 2-6 are during the double-blind phase (Month 0-3) and Visit 7 is during the single-blind phase (Month 4-14). Vaccine administration takes place during visits 2, 4, and 5 (Visit 2 = Dose 1; Visit 4 = Dose 2; Visit 5 = Dose 3). Field-worker Visits: During the double-blind phase, clinical visits are accompanied by daily field-worker visits subsequent to each vaccine administration visit. Additional field-worker visits also take place during months 4 to 13 of the single-blind phase. This form should be filled in if any unsolicited non-serious adverse events occurs during the trial period within 30 days post-vaccination. Please report all serious adverse events only on the Serious Adverse Event (SAE) report. Note that informed consent has to be obtained prior to any study procedure.

Link

https://clinicaltrials.gov/ct2/show/NCT00307021

Palavras-chave

  1. 24/08/2021 24/08/2021 -
Titular dos direitos

GlaxoSmithKline

Transferido a

24 de agosto de 2021

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Safety & Immunogenicity of two GSK Biologicals' Candidate Malaria Vaccines in young children, NCT00307021

Non-Serious Adverse Events

Administrative Documentation
Descrição

Administrative Documentation

Alias
UMLS CUI-1
C1320722
Subject number
Descrição

Subject number

Tipo de dados

integer

Alias
UMLS CUI [1]
C2348585
Non-Serious Adverse Events
Descrição

Non-Serious Adverse Events

Alias
UMLS CUI-1
C1518404
Has any non-serious adverse events occurred within one month (minimum 30 days) post-vaccination, excluding those recorded on the Solicited Adverse Events pages?
Descrição

If yes, please complete the following item group for each non-serious adverse event.

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0042196
UMLS CUI [2,1]
C0332300
UMLS CUI [2,2]
C0877248
UMLS CUI [2,3]
C1517001
Non-Serious Adverse Events
Descrição

Non-Serious Adverse Events

Alias
UMLS CUI-1
C1518404
AE Number
Descrição

Non-serious adverse events number

Tipo de dados

integer

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0600091
Description
Descrição

Non-serious adverse event description

Tipo de dados

text

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0678257
Location
Descrição

Non-serious adverse event anatomic site

Tipo de dados

text

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C1515974
For GSK
Descrição

Clinical study sponsor comment

Tipo de dados

text

Alias
UMLS CUI [1,1]
C2347796
UMLS CUI [1,2]
C0947611
Date started
Descrição

Non-serious adverse event start date

Tipo de dados

date

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0808070
During immediate post-vaccination period (60 minutes)?
Descrição

Non-serious adverse event start date immediately post vaccination

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0808070
UMLS CUI [1,3]
C0042196
UMLS CUI [1,4]
C0687676
UMLS CUI [1,5]
C0205253
Date stopped
Descrição

Non-serious adverse event end date

Tipo de dados

date

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0806020
Maximum intensity
Descrição

Non-serious adverse event maximum symptom intensity

Tipo de dados

text

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0518690
UMLS CUI [1,3]
C0806909
Relationship to investigational products: Is there a reasonable possibility that the AE may have been caused by the investigational product?
Descrição

Non-serious adverse event relationship to investigational products

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0013230
UMLS CUI [1,3]
C0439849
Outcome
Descrição

Non-serious adverse event outcome

Tipo de dados

text

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C1705586

Similar models

Non-Serious Adverse Events

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Administrative Documentation
C1320722 (UMLS CUI-1)
Subject number
Item
Subject number
integer
C2348585 (UMLS CUI [1])
Item Group
Non-Serious Adverse Events
C1518404 (UMLS CUI-1)
Non-serious adverse event post vaccination | excluding solicited adverse events
Item
Has any non-serious adverse events occurred within one month (minimum 30 days) post-vaccination, excluding those recorded on the Solicited Adverse Events pages?
boolean
C1518404 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0332300 (UMLS CUI [2,1])
C0877248 (UMLS CUI [2,2])
C1517001 (UMLS CUI [2,3])
Item Group
Non-Serious Adverse Events
C1518404 (UMLS CUI-1)
Non-serious adverse events number
Item
AE Number
integer
C1518404 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Non-serious adverse event description
Item
Description
text
C1518404 (UMLS CUI [1,1])
C0678257 (UMLS CUI [1,2])
Item
Location
text
C1518404 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
CL Item
Administration sites ([L])
(Comment:en)
CL Item
Non-administration site ([G])
(Comment:en)
Clinical study sponsor comment
Item
For GSK
text
C2347796 (UMLS CUI [1,1])
C0947611 (UMLS CUI [1,2])
Non-serious adverse event start date
Item
Date started
date
C1518404 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
Non-serious adverse event start date immediately post vaccination
Item
During immediate post-vaccination period (60 minutes)?
boolean
C1518404 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0687676 (UMLS CUI [1,4])
C0205253 (UMLS CUI [1,5])
Non-serious adverse event end date
Item
Date stopped
date
C1518404 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
Item
Maximum intensity
text
C1518404 (UMLS CUI [1,1])
C0518690 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
CL Item
Mild ([1])
CL Item
Moderate ([2])
CL Item
Severe ([3])
Non-serious adverse event relationship to investigational products
Item
Relationship to investigational products: Is there a reasonable possibility that the AE may have been caused by the investigational product?
boolean
C1518404 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
Item
Outcome
text
C1518404 (UMLS CUI [1,1])
C1705586 (UMLS CUI [1,2])
CL Item
Recovered / resolved ([1])
(Comment:en)
CL Item
Recovering / resolving ([2])
(Comment:en)
CL Item
Not recovered / not resolved ([3])
(Comment:en)
CL Item
Recovered with sequelae / resolved with sequelae ([4])
(Comment:en)

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial